Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Elevar Therapeutics
Pharma
Novo, Merck, Hengrui-Elevar—Fierce Pharma Asia
In two deals potentially worth $2 billion each, Novo gained a "triple G" candidate from United Labs as Merck bought a CV asset from Hengrui.
Angus Liu
Mar 28, 2025 9:28am
FDA rejects Hengrui, Elevar's PD-1 cancer drug combo—again
Mar 21, 2025 3:25pm
Sanofi, GSK and China reimbursement updates—Fierce Pharma Asia
Dec 6, 2024 9:00am
Inside the FDA concerns that sank Hengrui's PD-1 drug filing
Jul 16, 2024 4:50pm
Eisai, Takeda, BIOSECURE—Fierce Pharma Asia
Jul 12, 2024 9:05am
UPDATED: Elevar, Hengrui eye accelerated refile for PD-1 combo
Jul 12, 2024 12:08am
